10-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl}-N,N-dimethyl-10H-phenothiazine-2-sulfonamide

• ChemBase ID: 1397
• Molecular Formular: C24H33N3O3S2
• Molecular Mass: 475.66712
• Monoisotopic Mass: 475.19633393
• SMILES: S1c2c(N(CCCN3CCC(CC3)CCO)c3c1cccc3)cc(S(=O)(=O)N(C)C)cc2
• Canonical SMILES: OCCC1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C
• InChI: InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3
• InChIKey: JOMHSQGEWSNUKU-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 10-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl}-N,N-dimethyl-10H-phenothiazine-2-sulfonamide
• IUPAC Traditional name: pipotiazine
• Brand Name: Piportil; Piportil Depot; Piportil L4
• Synonyms: Pipothiazine; Pipotiazina [inn-spanish]; Pipotiazinum [inn-latin]; Pipotiazine

Database IDs

• CAS Number: 39860-99-6
• PubChem SID: 160964857; 46508263
• PubChem CID: 62867
• ATC CODE: N05AC04
• CHEMBL: 398880
• Chemspider ID: 56598
• DrugBank ID: DB01621
• KEGG ID: D08385
• Unique Ingredient Identifier: L903J9JPYV
• Wikipedia Title: Pipotiazine

CALCULATED PROPERTIES

JChem

• Acid pKa: 17.086569
• H Acceptors: 5
• H Donor: 1
• LogD (pH = 5.5): 0.0069175824
• LogD (pH = 7.4): 1.6610992
• Log P: 3.1296136
• Molar Refractivity: 134.1231 cm^3
• Polarizability: 52.15257 Å^3
• Polar Surface Area: 64.09 Å^2
• Rotatable Bonds: 7
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 3.94
• LOG S: -4.57
• Solubility (Water): 1.27e-02 g/l

PROPERTIES

Pharmacology Properties

• Admin Routes: Oral, IM
• Legal Status: Rx-only

DETAILS

DrugBank - DB01621

• Drug Groups: approved
• Description: Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
• Indication: For the maintenance treatment of chronic non-agitated schizophrenic patients.
• Pharmacology: Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It reduces activity of dopamine receptors in the limbic system. Its 5-HT antagonism helps normalize dopamine activity in the cortical regions.
• Toxicity: Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
• Affected Organisms: Humans and other mammals